Buserelin

Buserelin

Clinical data
Synonyms	D-Ser(Tbu)6EA10LHRH
Pregnancy category	X
Routes of administration	implant, intranasal
ATC code	L02AE01 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Pharmacokinetic data
Elimination half-life	72 to 80 minutes
Excretion	Renal
Identifiers
CAS Number	57982-77-1
PubChem CID	50225
DrugBank	HMDB03170
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C62H90N16O15
Molar mass	1299.48 g/mol

WikiDoc Resources for Buserelin
Articles
Most recent articles on Buserelin Most cited articles on Buserelin Review articles on Buserelin Articles on Buserelin in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Buserelin Images of Buserelin Photos of Buserelin Podcasts & MP3s on Buserelin Videos on Buserelin
Evidence Based Medicine
Cochrane Collaboration on Buserelin Bandolier on Buserelin TRIP on Buserelin
Clinical Trials
Ongoing Trials on Buserelin at Clinical Trials.gov Trial results on Buserelin Clinical Trials on Buserelin at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Buserelin NICE Guidance on Buserelin NHS PRODIGY Guidance FDA on Buserelin CDC on Buserelin
Books
Books on Buserelin
News
Buserelin in the news Be alerted to news on Buserelin News trends on Buserelin
Commentary
Blogs on Buserelin
Definitions
Definitions of Buserelin
Patient Resources / Community
Patient resources on Buserelin Discussion groups on Buserelin Patient Handouts on Buserelin Directions to Hospitals Treating Buserelin Risk calculators and risk factors for Buserelin
Healthcare Provider Resources
Symptoms of Buserelin Causes & Risk Factors for Buserelin Diagnostic studies for Buserelin Treatment of Buserelin
Continuing Medical Education (CME)
CME Programs on Buserelin
International
Buserelin en Espanol Buserelin en Francais
Business
Buserelin in the Marketplace Patents on Buserelin
Experimental / Informatics
List of terms related to Buserelin

Buserelin is a Gonadotropin-releasing hormone agonist (GnRH agonist). By causing constant stimulation of the pituitary, it decreases pituitary secretion of gonadotropins luteinizing hormone (LH) and follicle stimulating hormone (FSH). Like other GnRH agonists, buserelin may be used in the treatment of hormone-responsive cancers such as prostate cancer or breast cancer, estrogen-dependent conditions (such as endometriosis or uterine fibroids), and in assisted reproduction.

It is normally delivered via a nasal spray but is also available as an injection.

Buserelin acetate is marketed by Sanofi-Aventis under the brand name Suprefact.